IP Library Granted Patent US 10,676,773
Granted Patent B2
US 10,676,773 · App. 15/555,594 · Granted Jun 9, 2020

Antibodies conjugatable by transglutaminase and conjugates made therefrom

Inventors: Chetana Rao-Naik (Walnut Creek, CA); Shrikant Deshpande (Fremont, CA)
Assignee: Bristol-Myers Squibb Company
C12P21/02A61K47/6803A61K47/6811A61K47/6849A61K47/6851A61K47/6889C07K16/28C07K16/30C12Y203/02013C07K16/2875C07K2317/51C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,773
App. No.
15/555,594
Granted
Jun 9, 2020
Kind
B2
Abstract

An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.

Claims (6)

1. A full length antibody, wherein at least one heavy chain has a C-terminal extension having an amino acid sequence consisting of EEQYASTY (SEQ ID NO:1) or EEQYQSTY (SEQ ID NO:2).

2. A full length antibody according to claim 1 , wherein the C-terminal extension has an amino acid sequence consisting of EEQYASTY (SEQ ID NO:1).

3. A full length antibody according to claim 1 , wherein the C-terminal extension has an amino acid sequence consisting of EEQYQSTY (SEQ ID NO:2).

4. An antibody-drug conjugate wherein the antibody is covalently linked to a drug moiety via an amide bond at the side chain of a glutamine residue in a C-terminal extension of a heavy chain of the antibody, the C-terminal extension having an amino acid sequence consisting of EEQYASTY (SEQ ID NO:1) or EEQYQSTY (SEQ ID NO:2).

5. An antibody-drug conjugate according to claim 4 , wherein the C-terminal extension has an amino acid sequence consisting of EEQYASTY (SEQ ID NO:1).

6. An antibody-drug conjugate according to claim 4 , wherein the C-terminal extension has an amino acid sequence consisting of EEQYQSTY (SEQ ID NO:2).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2018
From: DESHPANDE, SHRIKANT; RAO-NAIK, CHETANA
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 045264/0270 →
Continuity (2)
Provisional Application 62130673 · Mar 10, 2015
Related Publication 20180037921A1 · Feb 8, 2018